EOLS - エボラス (Evolus Inc.) エボラス

 EOLSのチャート


 EOLSの企業情報

symbol EOLS
会社名 Evolus Inc (エボラス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エヴォルス(Evolus Inc.)は医療美容会社である。同社は医師および美容処置・治療法を提供することに重点を置く。また、自費の美容市場を提供することに焦点を当てる。製品候補であるPrabotulinumtoxinA(DWP-450)は大規模かつ成長的美容市場のニーズに対応する注入可能な900キロダルトンのボツリヌス毒素タイプである。同社は医師と患者にDWP-450による提案を提供する。OnabotulinumtoxinA(BOTOX)は米国にある神経毒素認可900kDaボツリヌス毒素A型複合体である。   エボラスは米国の医療審美企業。医師および患者に審美・美容手術や治療法での広範な選択肢を提供する。また、自己負担における医療市場に注力する。主な候補薬には、市場でニ―ズの高い900キロダルトン分子形態のA型ボツリヌス毒素注射剤「DWP-450」などがある。本社所在地はカリフォルニア州ア―バイン。   Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.
本社所在地 17901 Von Karman Avenue Suite 150 Irvine CA 92614 USA
代表者氏名 Vikram Malik ヴィクラム・マリク
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 949-284-4555
設立年月日 41214
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.evolus.com
nasdaq_url https://www.nasdaq.com/symbol/eols
adr_tso
EBITDA EBITDA(百万ドル) -18.51500
終値(lastsale) 16.43
時価総額(marketcap) 438270102.13
時価総額 時価総額(百万ドル) 438.27010
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 411.15510
当期純利益 当期純利益(百万ドル) -17.56000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Evolus Inc revenues was not reported. Net loss increased from $6.3M to $22.6M. Higher net loss reflects Revaluation of contingent royalty obliga increase from $0K to $9.1M (expense) General and Administrative - Balancing v increase from $1.8M to $6.8M (expense) Stock-based Compensation in SGA increase from $232K to $2.9M (expense).

 EOLSのテクニカル分析


 EOLSのニュース

   Evolus (NASDAQ:EOLS) Price Target Raised to $18.00 at Truist Financial  2023/05/28 08:42:10 The AM Reporter
Evolus (NASDAQ:EOLS – Get Rating) had its target price boosted by equities researchers at Truist Financial from $14.00 to $18.00 in a research note issued to investors on Friday, The Fly reports. Truist Financial’s price objective points to a potential upside of 105.01% from the stock’s current price. A number of other brokerages have also […]
   This Analyst Likes Evolus As ''Top Play In Aesthetics''  2023/05/10 18:27:21 Benzinga
Evolus Inc (NASDAQ: EOLS ) will be the exclusive U.S. distributor for five dermal fillers currently in late-stage development from Symatese, a French regenerative medical solutions company . The addition expands the company''s total addressable U.S. market by 70% by adding a $1.6 billion U.S. filler market opportunity to the existing $2.3 billion aesthetic neurotoxin market. Both markets are expected to nearly double by 2028. The company has raised its 2028 revenue outlook to $700 million, with revenue expectation for the organic growth of Jeuveau to $500 million remaining unchanged. Evolus will pay Symatese €16.2 million, including an upfront payment of €4.1 million and … Full story available on Benzinga.com
   Evolus, Inc. (EOLS) Q1 2023 Earnings Call Transcript  2023/05/10 02:53:01 Seeking Alpha
Evolus, Inc. (NASDAQ:NASDAQ:EOLS) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ETCompany ParticipantsDavid Erickson - VP, IRDavid Moatazedi - President and CEORui Avelar - CMO and…
   Evolus: Q1 Earnings Insights  2023/05/09 20:15:15 Benzinga
Evolus (NASDAQ: EOLS ) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Evolus missed estimated earnings by 73.33%, reporting an EPS of $-0.26 versus an … Full story available on Benzinga.com
   Evolus GAAP EPS of -$0.26 misses by $0.01, revenue of $41.7M beats by $1.18M  2023/05/09 20:08:18 Seeking Alpha
Evolus press release (EOLS): Q1 GAAP EPS of -$0.26 misses by $0.01.Revenue of $41.7M (+23.0% Y/Y) beats by $1.18M.Evolus continues to expect total net revenues for the full year 2023…
   Evolus, Inc. (EOLS) Q4 2022 Earnings Call Transcript  2023/03/09 02:36:02 Seeking Alpha
Evolus, Inc. (NASDAQ:NASDAQ:EOLS) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ETCompany ParticipantsDavid Erickson - Vice President of Investor RelationsDavid Moatazedi -…
   Evolus GAAP EPS of -$0.23 misses by $0.02, revenue of $43.65M misses by $0.17M  2023/03/08 21:12:35 Seeking Alpha
Evolus press release (EOLS): Q4 GAAP EPS of -$0.23 misses by $0.02.Revenue of $43.65M (+25.9% Y/Y) misses by $0.17M.Outlook: Evolus continues to expect total net revenues for full…
   Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update  2023/03/08 21:05:00 Business Wire
NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus reports financial results for the fourth quarter and full year ended December 31, 2022 and provides a business update
   Evolus Q4 2022 Earnings Preview  2023/03/07 18:38:17 Seeking Alpha
Evolus (EOLS) is scheduled to announce Q4 earnings results on Wednesday, March 8th, after market close.The consensus EPS Estimate is -$0.14 and the consensus Revenue Estimate is $43.82M…
   Preview: Evolus''s Earnings  2023/03/07 16:02:35 Benzinga
Evolus (NASDAQ: EOLS ) is set to give its latest quarterly earnings report on Wednesday, 2023-03-08. Here''s what investors need to know before the announcement. Analysts estimate that Evolus will report an earnings per share (EPS) of $-0.15. Evolus bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
   "Extra-Strength" Formulation of Jeuveau Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance  2023/01/28 13:00:00 Wallstreet:Online
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau (prabotulinumtoxinA-xvfs), its flagship neurotoxin product, at the 2023 International Master Course on Aging Science (IMCAS)
   Evolus Receives Regulatory Approval for Nuceiva in Australia  2023/01/23 14:00:00 Wallstreet:Online
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva (prabotulinumtoxinA)▼, a neurotoxin dedicated exclusively to aesthetics. Nuceiva was approved for the temporary improvement in the appearance
   Evolus Receives Regulatory Approval for Nuceiva® in Australia  2023/01/23 14:00:00 Business Wire
NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva®.
   Why Evolus Shares Jumped This Week  2023/01/20 18:54:32 The Motley Fool
The company said it expects to turn a profit in the fourth quarter.
   Here''s Why This Analyst Seems Highly Convinced With Evolus'' Outlook  2023/01/19 18:15:34 Benzinga
Evolus Inc (NASDAQ: EOLS ) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. Additionally, the company issued revenue guidance for the full-year 2023 of $180 million - $190 million and expects non-GAAP operating income to be positive in the fourth quarter of 2023 . The company has set a 2028 revenue target of $500 million, a 22% CAGR. With a Buy rating, Mizuho has raised the

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エボラス EOLS Evolus Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)